ClinicalTrials.gg
CompletedNCT03325920DIABRUXUpdated Mar 11, 2021

Validation of a Diagnostic Method for Quantification of Sleep Bruxism

An interventional study of DIABRUX in Sleep Bruxism and Diagnosis, sponsored by Heinrich-Heine University, Duesseldorf. Completed at 1 site in Germany. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-11.

Sponsored by Heinrich-Heine University, Duesseldorf · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

This study aims to validate a new diagnostic method for quantification and monitoring of sleep bruxism.

Read the detailed description

Sleep bruxism has characteristically been defined by the American Academy of Sleep Medicine as 'an oral activity characterized by grinding or clenching of the teeth during sleep, usually associated with sleep arousals'. For sleep bruxism diagnosis, to date the polysomnographic recordings represent the highest standard for sleep bruxism diagnosis, but they are concomitantly associated with disadvantages which include technical complexity, limited availability, and the fact that they are time-consuming and cost-intensive. Recently, a prototype of a diagnostic plate has been developed which allows a fully-automatic, computer-based quantification of abrasion thereupon for the assessment of sleep bruxism activity. The results of the pilot study were promising, and therefore, the aim of the present study is to refine and validate this new diagnostic method for quantification and monitoring of sleep bruxism.

02

Conditions studied

  • Sleep Bruxism
  • Diagnosis

Keywords

  • sleep bruxism
  • diagnosis
  • validation study
  • assessment
03

In context

Sleep Bruxism

62 studies on the registry are indexed under Sleep Bruxism; 11 are open to participants now.

This study's enrollment of 45 is above the median of 39 across 38 interventional studies indexed under Sleep Bruxism.

Browse Sleep Bruxism studies →

Lead sponsor

Heinrich-Heine University, Duesseldorf is the lead sponsor of 180 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has signed and understood the approved form and is able to meet the proposed study proceedings
  • for the sleep bruxism Group: subjects have to fulfill the clinical criteria of the American Academy of Sleep Medicine (sleeping partner's Report of grinding sounds during sleep within the last 6 months, plus at least one of the following symptoms: abnormal attrition of the teeth or shiny spots on dental restorations, hypertrophy of the masseteric muscle upon palpation, and/or self-report of muscle fatigue on awakening. In addition to the clinical criteria for sleep bruxism diagnosis, the following polysomnographic criteria have to be present: bruxism episodes/hr >4, bruxism burst/hr >25, at least one episode of grinding per sleep period

Subjects that do not meet any of the clinical or polysomnographic criteria for sleep bruxism were included into the non-sleep bruxism group.

Exclusion criteria

Exclusion Criteria:

  • current participation in another interventional Investigation
  • cardiac Pacemaker
  • central nervous system and peripheral nervous system disorders
  • use of sedating medications and/or psychopharmacologically effective drugs
  • suspected severe psychological disorder (for example schizophrenia)
  • a lack of German language
  • drug and/or alcohol abuse
  • pregnancy or breast-feeding

Participants of the sleep bruxism group that do not meet any of the clinical or polysomnographic criteria for sleep bruxism were excluded from the sleep bruxism group.

Participants of the non-sleep bruxism group that fulfill the clinical and/or polysomnographic criteria for sleep bruxism were excluded from the non-sleep bruxism group.

Further dental exclusion criteria are:

  • prostheses or extensive prosthetic restorations
  • dental functional treatment during the last 6 months
  • gross malocclusion
  • too many missing teeth that omit fabricating a diagnostic plate
  • fixed brace
  • temporomandibular dysfunction requiring treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Sleep bruxism group

    25 sleep bruxism subjects wear the DIABRUX for five consecutive nights.

    Device: DIABRUX

  • Experimental
    non-sleep bruxism group

    25 non-sleep bruxism subjects wear the DIABRUX for five consecutive nights.

    Device: DIABRUX

Interventions

  • DeviceDIABRUX

    All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.

    Also known as: Diagnostic plate

06

What researchers measure

Primary outcomes

  1. Pixel score of the diagnostic plate

    Quantitative measure of sleep bruxism activity

    Time frame: The DIABRUX plate should be worn for five consecutive nights. This will be performed by each participant at the earliest of the 12th and not later than the 85th days after screening.

Secondary outcomes

  1. Psychologic load

    Psychologic load will be estimated by means of the Symptom-Check-List-90 Standard (SCL-90-S; Franke, 1995) measuring subjective complaints, as well as physical and mental impairments. This self-assessment questionnaire implies 90 items with a total of 9 different scales: somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism and seven supplementary questions. Every item starts with "For the past week, how much were you bothered by" followed by 90 different symptoms. The items are Likert scaled with a range from 0 ("not at all") to 4 ("extremely"), whereby higher values represent a higher psychological load. Three global indices are reported via the SCL-90-S, viz. the Global Severity Index (GSI), the Positive Symptom Total (PST), and the Positive Symptom Distress Index (PSDI). The higher the score of each index, the greater is the psychological load.

    Time frame: Subjects who fulfill the inclusion criteria and none of the exclusion criteria should stipulate the first visit not later than 28 days after screening (day 0).

  2. Oral health-related quality of life

    Oral health-related quality of life will be recorded with the Oral Health Impact Profile German 14 (OHIP-G14; Slade, 1997). The OHIP-G14 measures the subjective experience in terms of oral health (teeth, mouth, jaw and denture). It contains 14 questions (e.g. "Have you had painful aching in your mouth?") which are Likert scaled from 0 ("never") to 4 ("very often"). All questions refer to the last month. There are 7 different dimensions with two questions each (functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability and handicap). Values can be summed up to a total score, ranging between 0 and 56. Higher scores represent a more negative experience with one's oral health.

    Time frame: Recorded during the 1. visit; this appointment may happen between the 1st-28th day of study participation.

  3. Pain perception

    Pain perception will be calculated using the pain perception scale (Schmerzempfindungsskala, SES; Geissner, 1996). The SES is a self-assessment questionnaire for describing the subjective pain perception. It consists of two parts (part A with 14 items and part B with 10 item) which form two global scales: A = affective pain perception and B = sensoric pain perception. Every single item is based on adjective sentences like "I feel my pain is burning". Items are Likert scaled with a range from 1 ("this is not true") to 4 ("this is exactly true"). Higher values correspond to a painfully experience and represent a worse outcome. Item values are summed for every scale, therefore the scale range A is from 14 to 56 and the scale range B is from 10 to 40. Raw scale values can be transferred into the percent range.

    Time frame: Recorded during the 1. visit; this appointment may happen between the 1st-28th day of study participation.

  4. Dream experience

    Aspects of dream experience will be assessed using the Mannheim Dream Questionnaire (MADRE; Schredl et al., 2014) combined with a dream protocol. These include dream recall, dream types, attitude towards dreaming, what dreamers do with their dreams, and effects of dreaming on waking life. Every item measures a single aspect of dreaming and the response format gathers information about frequencies (e.g. "every morning" or "less than once a month") and contents (e.g. topics of nightmares in childhood). Scaling of the items varies between 3 to 8 points and they range between 0 (least degree of manifestation/frequency) and maximum 8 (highest degree of manifestation/frequency). No global score exists. There is one aggregate score concerning attitude towards dreams, that encompasses 6 items with a 5-point Likert scale (0 = "not at all" to 4 "totally"), e.g. "I think that dreaming is in general a very interesting phenomenon."

    Time frame: Recorded during the 2. and the 3. visit; this appointment may happen between the 2nd-57th day of study participation.

  5. Individual stress coping

    The stress coping questionnaire 78 (SVF-78; Janke et al., 1985) assesses individual long-term and constant strategies to cope with stress. The respondents determine by themselves how likely they apply 78 different coping styles. Coping styles refer to everyday situations. Every items starts with the phrase "If I was affected, disturbed or unsettled by someone or something", followed by a coping strategy (e.g. "I ask someone to help me"). Items are Likert scaled with a range from 0 ("not at all") to 4 ("very likely"). Higher values stand for a higher likelihood to apply the reaction in a certain situation. Two different main scales exist which sum up either positive strategies (adaptive strategies) or negative strategies (maladaptive strategies). Higher scores in positive strategies represent a stress reductive coping style. Higher scores in negative strategies represent a stress enhancing coping style. Raw values can be transferred to standardized T-scores.

    Time frame: Recorded during the 4. visit; this appointment may happen between the 5th-71th day of study participation.

  6. State-trait-Anxiety

    The State-Trait-Anxiety Inventory (STAI; Laux et al. 1981) consists of 2 questionnaires with 20 items, respectively, and provides 20 different statements to describe ones feelings of anxiety at the moment. Half of the statements contain anxiety-present (e.g. "I feel over-excited and rattled"), the other half anxiety-absent items (e.g. "I am relaxed"). 4-point Likert scales are used with values from 1 ("not at all") to 4 ("very much so"). The trait anxiety scale comprises 20 statements to describe feelings of anxiety in general. 13 statements involve anxiety-present (e.g. "I lack self-confidence") and 7 anxiety-absent items (e.g. "I feel secure"). 4-point Likert scales allow data indication with values from 1 ("almost never") to 4 ("almost always"). The range of values is between 20 and 40 for each scale. The higher the score the more intense is the feeling of anxiety or, in relation to trait anxiety, the heavier is the anxiety disorder.

    Time frame: Recorded during the 4. visit; this appointment may happen between the 5th-71th day of study participation.

  7. Subjective rating of the DIABRUX characteristics

    Subjective rating of the device characteristics will be evaluated by using a short questionnaire.

    Time frame: The short questionnaire should be returned to the site together with the used DIABRUX plate. This will be performed by each participant at the earliest of the 12th and not later than the 85th days after screening.

Other outcomes

  1. Assessment of probable sleep bruxism (clinical AASM criteria)

    Probable sleep bruxism will be estimated by combining self-report plus the inspection part of a clinical dental examination according to the clinicial AASM criteria (AASM, 2005).

    Time frame: Recorded during the 1. visit; this appointment may happen between the 1st-28th day of study participation.

  2. Assessment of probable awake bruxism

    Awake bruxism (diurnal clenching) will be measured on the basis of self-report plus the inspection part of a clinical examination.

    Time frame: Recorded during the 1. visit; this appointment may happen between the 1st-28th day of study participation.

  3. Presence of different forms of temporomandibular disorders

    The presence of different forms of temporomandibular disorders will be verified by means of the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD).

    Time frame: Recorded during the 1. visit; this appointment may happen between the 1st-28th day of study participation.

07

Study locations

1 site
  • Poliklinik für Zahnerhaltung, Parodontologie und Endodontologie Universitätsklinikum der Heinrich-Heine- Universität Düsseldorf
    Düsseldorf, NRW 40225, Germany
08

References and documents

Publications

  • Ommerborn MA, Giraki M, Schneider C, Schaefer R, Gotter A, Franz M, Raab WH. A new analyzing method for quantification of abrasion on the Bruxcore device for sleep bruxism diagnosis. J Orofac Pain. 2005 Summer;19(3):232-8. PubMed 16106717 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jul 2020, 14 months.

Of 19 interventional studies with no phase under Sleep Bruxism, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 14 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2017
First posted
Oct 30, 2017
StartActual
May 20, 2019
Primary completionActual
Jul 31, 2020
CompletionActual
Jul 31, 2020
Last update
Mar 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03325920
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
May 20, 2019
Primary completion
Jul 31, 2020
Completion
Jul 31, 2020
Last update
Mar 11, 2021

Study contacts

Michelle A Ommerborn, Dr.
principal investigator · Universitätsklinikum Düsseldorf/Heinrich-Heine-University Düsseldorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion